Company · founded 2000
Actinium Pharmaceuticals (United States)
New York, United States · actiniumpharma.com
- Citations, last 5 years
- 93
- Works, last 5 years
- 43
- h-index
- 20
- Scientists listed
- 6
- Grants since 2016
- 3
Grants received
2020–2022 · research · R42
Iomab-ACT: A phase I/II study of 131-I apamistamab targeted lymphodepletion followed by CD19-targeted CAR T-cell therapy for patients with relapsed or refractory B-ALL or DLBCL
Mark S Berger · Actinium Pharmaceuticals (United States) · funded by National Institutes of Health
2020–2025 · research · R42
Iomab-ACT: A phase I/II study of 131-I apamistamab targeted lymphodepletion followed by CD19-targeted CAR T-cell therapy for patients with relapsed or refractory B-ALL or DLBCL
Avinash Desai · Actinium Pharmaceuticals (United States) · funded by National Institutes of Health
2020–2025 · research · R42
Iomab-ACT: A phase I/II study of 131-I apamistamab targeted lymphodepletion followed by CD19-targeted CAR T-cell therapy for patients with relapsed or refractory B-ALL or DLBCL
Avinash Desai · Actinium Pharmaceuticals (United States) · funded by National Institutes of Health